CCyR at 3, 6, and 12 months by therapy
. | 3 months . | 6 months . | 12 months . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Evaluable . | CCyR . | % . | P . | Evaluable . | CCyR . | % . | P . | Evaluable . | CCyR . | % . | P . | |
IM 400 mg | 70 | 27 | 39 | 70 | 37 | 53 | 68 | 45 | 66 | |||
IM 800 mg | 199 | 125 | 63 | < .001 | 194 | 164 | 85 | < .001 | 187 | 169 | 90 | < .001 |
Second TKI | 141 | 114 | 81 | 131 | 125 | 95 | 118 | 116 | 98 |
. | 3 months . | 6 months . | 12 months . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Evaluable . | CCyR . | % . | P . | Evaluable . | CCyR . | % . | P . | Evaluable . | CCyR . | % . | P . | |
IM 400 mg | 70 | 27 | 39 | 70 | 37 | 53 | 68 | 45 | 66 | |||
IM 800 mg | 199 | 125 | 63 | < .001 | 194 | 164 | 85 | < .001 | 187 | 169 | 90 | < .001 |
Second TKI | 141 | 114 | 81 | 131 | 125 | 95 | 118 | 116 | 98 |
Evaluable indicates patients who received therapy and were evaluable for cytogenetic response at each time point; and IM, imatinib.